Pfizer Says In Q2 2024, It Is Launching A Multi-Tear Program To Reduce Our Cost Of Goods Sold; First Phase Of Multi-Year Program To Reduce Cost Of Goods Sold Is Expected To Deliver Savings Of ~$1.5B By End Of 2027; Costs Will Be Recorded Primarily In...
Pfizer Says In Q2 2024, It Is Launching A Multi-Tear Program To Reduce Our Cost Of Goods Sold; First Phase Of Multi-Year Program To Reduce Cost Of Goods Sold Is Expected To Deliver Savings Of ~$1.5B By End Of 2027; Costs Will Be Recorded Primarily In...
輝瑞表示，將在2024年第二季度啓動一項多年度計劃，以降低我們的商品銷售成本；降低商品銷售成本的多年計劃的第一階段預計將在2027年底之前節省約15億美元；成本將主要記錄在...
Pfizer Says In Q2 2024, It Is Launching A Multi-Tear Program To Reduce Our Cost Of Goods Sold; First Phase Of Multi-Year Program To Reduce Cost Of Goods Sold Is Expected To Deliver Savings Of ~$1.5B By End Of 2027; Costs Will Be Recorded Primarily In 2024, With Cash Outlays Expected In 2025 And 2026; One-Time Costs To Achieve Savings Associated With First Phase Of Program Are Expected To Be About $1.7B
輝瑞表示，將在2024年第二季度啓動一項多年度計劃，以降低我們的商品銷售成本；降低商品銷售成本的多年計劃的第一階段預計將在2027年底之前節省約15億美元；成本將主要記錄在2024年，現金支出預計在2025年和2026年；實現與第一階段計劃相關的節省的一次性成本預計約爲17億美元
- Reuters
-路透社
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。